Rankings
▼
Calendar
SYRE
Spyre Therapeutics, Inc.
$3B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$19M
Gross Profit
$19M
100.0% margin
Operating Income
-$66M
-350.3% margin
Net Income
-$66M
-351.1% margin
EPS (Diluted)
$-25.02
Cash Flow
Operating Cash Flow
-$54M
Free Cash Flow
-$54M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$110M
Total Liabilities
$26M
Stockholders' Equity
$84M
Cash & Equivalents
$15M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$19M
$0
—
Gross Profit
$19M
-$2M
+1253.9%
Operating Income
-$66M
-$81M
+19.4%
Net Income
-$66M
-$81M
+18.7%
← Q4 2020
All Quarters
Q1 2021 →
SYRE FY 2021 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena